|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taniguchi H, Moriya C, Igarashi H, Saitoh
A, Yamamoto H, Adachi Y and Imai K: Cancer stem cells in human
gastrointestinal cancer. Cancer Sci. 107:1556–1562. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garvalov BK and Acker T: Cancer stem
cells: A new framework for the design of tumor therapies. J Mol Med
(Berl). 89:95–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Corbeil D, Karbanová J, Fargeas CA and
Jászai J: Prominin-1 (CD133): Molecular and cellular features
across species. Adv Exp Med Biol. 777:3–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin AH, Miraglia S, Zanjani ED,
Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck
DW: AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
7
|
Huang R, Mo D, Wu J, Ai H and Lu Y: CD133
expression correlates with clinicopathologic features and poor
prognosis of colorectal cancer patients: An updated meta-analysis
of 37 studies. Medicine (Baltimore). 97:e104462018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sukowati CHC: Heterogeneity of hepatic
cancer stem cells. Adv Exp Med Biol. 1139:59–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reyes EE, Gillard M, Duggan R, Wroblewski
K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ
and Griend DJ: Molecular analysis of CD133-positive circulating
tumor cells from patients with metastatic castration-resistant
prostate cancer. J Transl Sci. 1:2015.PubMed/NCBI
|
|
10
|
Chen E, Zeng Z, Bai B, Zhu J and Song Z:
The prognostic value of CSCs biomarker CD133 in NSCLC: A
meta-analysis. Oncotarget. 7:56526–56539. 2016.PubMed/NCBI
|
|
11
|
Ishigami S, Ueno S, Arigami T, Uchikado Y,
Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, et
al: Prognostic impact of CD133 expression in gastric carcinoma.
Anticancer Res. 30:2453–2457. 2010.PubMed/NCBI
|
|
12
|
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K
and Shirouzu K: Expression of CD133 in the cytoplasm is associated
with cancer progression and poor prognosis in gastric cancer.
Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomita H, Tanaka K, Tanaka T and Hara A:
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget.
7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang EH, Hynes MJ, Zhang T, Ginestier C,
Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde
dehydrogenase 1 is a marker for normal and malignant human colonic
stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cardoso R, Coburn NG, Seevaratnam R, Mahar
A, Helyer L, Law C and Singh S: A systematic review of patient
surveillance after curative gastrectomy for gastric cancer: A brief
review. Gastric Cancer. 15 (Suppl 1):S164–S167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ilhan E, Ureyen O and Meral UM: Ongoing
problems concerning 7th TNM staging system and proposals for 8th
TNM staging system of gastric cancer. Prz Gastroenterol.
11:223–225. 2016.PubMed/NCBI
|
|
21
|
Oo AKK, Calle AS, Nair N, Mahmud H,
Vaidyanath A, Yamauchi J, Khayrani AC, Du J, Alam MJ, Seno A, et
al: Up-regulation of PI 3-kinases and the activation of PI3K-Akt
signaling pathway in cancer stem-like cells through DNA
hypomethylation mediated by the cancer microenvironment. Transl
Oncol. 11:653–663. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang Q, Zhang Q, Wang S, Xie S, Fang W,
Liu Z, Liu J and Yao K: A fraction of CD133+ CNE2 cells
is made of giant cancer cells with morphological evidence of
asymmetric mitosis. J Cancer. 6:1236–1244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Network NCCN, . (NCCN) Clinical Practice
Guidelines in Oncology. Gastric cancer. version 1. 2018. 2018.
https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
|
|
24
|
Basch E, Iasonos A, McDonough T, Barz A,
Culkin A, Kris MG, Scher HI and Schrag D: Patient versus clinician
symptom reporting using the National Cancer Institute Common
Terminology criteria for adverse events: Results of a
questionnaire-based study. Lancet Oncol. 7:903–909. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mills JC and Shivdasani RA: Gastric
epithelial stem cells. Gastroenterology. 140:412–424. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng S, Yang X, Lassus H, Liang S, Kaur S,
Ye Q, Li C, Wang LP, Roby KF, Orsulic S, et al: Distinct expression
levels and patterns of stem cell marker, aldehyde dehydrogenase
isoform 1 (ALDH1), in human epithelial cancers. PLoS One.
5:e102772010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levi E, Sochacki P, Khoury N, Patel BB and
Majumdar AP: Cancer stem cells in Helicobacter pylori
infection and aging: Implications for gastric carcinogenesis. World
J Gastrointest Pathophysiol. 5:366–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li XS, Xu Q, Fu XY and Luo WS: ALDH1A1
overexpression is associated with the progression and prognosis in
gastric cancer. BMC cancer. 14:7052014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y,
Uraoka N, Anami K, Sentani K, Oue N and Yasui W: Expression of
cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and
lymph node metastasis of gastric cancer. Pathol Int. 62:112–119.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li K, Guo X, Wang Z, Li X, Bu Y, Bai X,
Zheng L and Huang Y: The prognostic roles of ALDH1 isoenzymes in
gastric cancer. Onco Targets Ther. 9:3405–3414. 2016.PubMed/NCBI
|
|
32
|
Biddle A, Liang X, Gammon L, Fazil B,
Harper LJ, Emich H, Costea DE and Mackenzie IC: Cancer stem cells
in squamous cell carcinoma switch between two distinct phenotypes
that are preferentially migratory or proliferative. Cancer Res.
71:5317–5326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu L, Wu M, Sun L, Li W, Fu W, Zhang X and
Liu T: Clinicopathological and prognostic significance of cancer
stem cell markers CD44 and CD133 in patients with gastric cancer: A
comprehensive meta-analysis with 4,729 patients involved. Medicine
(Baltimore). 95:e51632016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HH, Seo KJ, An CH, Kim JS and Jeon HM:
CD133 expression is correlated with chemoresistance and early
recurrence of gastric cancer. J Surg Oncol. 106:999–1004. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W,
Sun YM, Chen FL and Jin XM: Expressions of putative cancer stem
cell markers ABCB1, ABCG2, and CD133 are correlated with the degree
of differentiation of gastric cancer. Gastric Cancer. 15:440–450.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu JW, Wang SL, Wu JG, Lu RQ, Ni XC, Cai C
and Jiang BJ: Study on the biological characteristics of CD133(+)
cells interfered by RNA interference in gastric cancer. ISRN
Gastroenterol. 2014:3295192014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu Y, Yu J, Wang S, Lu R, Wu J and Jiang
B: Overexpression of CD133 enhances chemoresistance to
5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric
cancer cells. Oncol Rep. 32:2437–2444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paoletti X, Oba K, Burzykowski T, Michiels
S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, et al:
GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research
International Collaboration) Group: Benefit of adjuvant
chemotherapy for resectable gastric cancer: A meta-analysis. JAMA.
303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu T, Li W, Sun Y and Shen K: Adjuvant
chemotherapy for gastric cancer: Less drug, same efficacy. J Clin
Oncol. 29:1142011. View Article : Google Scholar
|
|
40
|
Larzabal L, El-Nikhely N, Redrado M,
Seeger W, Savai R and Calvo A: Differential effects of drugs
targeting cancer stem cell (CSC) and non-CSC populations on lung
primary tumors and metastasis. PLoS One. 8:e797982013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Świerczewska M, Klejewski A, Brązert M,
Kaźmierczak D, Iżycki D, Nowicki M, Zabel M and Januchowski R: New
and old genes associated with primary and established responses to
paclitaxel treatment in ovarian cancer cell lines. Molecules.
23:E8912018. View Article : Google Scholar : PubMed/NCBI
|
